EPISODE 2
Unmet Needs in IgAN:
Burden of Disease & Long-Term Impact
on Patients Ft. Dr. Jonathan Barratt
MA-SP-24-0010
Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine, College of Life Sciences at University of Leicester,
discusses key take-aways from his presentation on long-term IgA nephropathy management during
Travere Therapeutics’ 2023 Summit, an interactive 1.5-day gathering of the world’s glomerular disease experts.
Also find us on:
Apple Podcasts
Spotify
Vimeo
Episode Summary
“If you have IgA Nephropathy and you’re diagnosed as a child, half of those children have developed kidney failure at 20 years.”
“We need to be thinking, what is it like for that patient in front of us being 50 or 60, not necessarily what’s going to happen in the next five or ten years.”
“If we don’t think the longer term, we’re going to under-treat and not serve our patients well.”
- IgA nephropathy patients often have decades of life ahead of them, so physicians should focus on minimizing lifetime risk of kidney failure rather than short-term outcomes (00:02:11)
- RaDaR data shows high rates of kidney failure among IgA nephropathy patients in the UK, even those diagnosed and treated as children (00:04:05)
- Per the RaDaR publication, an eGFR decline of <1 ml/min per 1.73 m2 per year must be the target if patients are to avoid kidney failure (00:06:48)
- In the UK, 1 in 4 IgA nephropathy patients with 0.5-1 g/day proteinuria reach ESRD within 10 years (00:08:23)
- Recent US database searches confirm high rates of CKD progression and kidney failure in IgA nephropathy patients, even those with lower proteinuria levels (00:13:20)
MA-SP-24-0034
More Episodes Like This
Contact Us
For more information, please click on the link below to be directed to our contact us form.
Adverse Event Reporting
To report suspected adverse reactions, contact Travere Therapeutics at 1-877-659-5518 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
MA-DS-24-0002